Figure 3.
The journey of the patient with hereditary angioedema (HAE): management of HAE; 3.1, 3.2, 3.3, and 3.4 refer to expert perspectives detailed in the text under the heading “Journey of the Patient with HAE” and the subheading “Stage 3: Management of HAE.” *If a C1 inhibitor (C1-INH), a kallikrein inhibitor, or a bradykinin receptor antagonist is unavailable, then solvent/detergent-treated plasma (SDP) or frozen plasma may be considered (Ref. 15). †C1-INH and androgens are both options for short-term prophylaxis. ‡Due to a lack of supportive efficacy data, antifibrinolytics are not recommended for long-term prophylaxis, but they may have some benefit in a minority of cases when other options are not available or feasible (Ref. 15). See published guidelines for more detailed information regarding the recommended use of these treatments (Refs. 13–18); in addition, the availability and licensing of treatments for HAE may vary worldwide, and the recommendation is to consult local prescribing information.